Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)
Status:
Completed
Trial end date:
2021-06-09
Target enrollment:
Participant gender:
Summary
This is a Phase 3, multicenter, double-blind, randomized, placebo-controlled study to
evaluate the safety and efficacy of iloprost on the frequency of and relief from symptomatic
digital ischemic episodes in subjects with systemic sclerosis.